United States Ebola Virus Vaccine Market 2033 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

The Global Ebola Virus Vaccine Market reached US$173.82 million in 2024 and is expected to reach US$288.41 million by 2033, growing at a CAGR of 6.4 % during the forecast period 2025-2033, according to DataM intelligence research.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/ebola-virus-vaccine-market?sb

Key Development:

United States: Recent Ebola Vaccine Developments

✅ In December 2025, the Democratic Republic of the Congo officially declared the end of its 2025 Zaire Ebola outbreak after no new cases were reported, highlighting progress in outbreak control where WHO‐recommended vaccination campaigns played a key role.

✅ In November 2025, WHO‐supported Ebola vaccination began in the Democratic Republic of the Congo's Kasai Province to protect frontline health workers and contacts of confirmed Ebola cases using doses from the global stockpile.

✅ In September 2025, the World Health Organization and partners delivered initial shipments of the Ervebo Ebola vaccine to Congo's outbreak epicentre, initiating ring vaccination efforts targeting high‐risk populations and responders.

✅ In September 2025, health authorities confirmed the deployment of Ervebo vaccine doses from pre‐positioned stockpiles in Kinshasa for frontline and contact vaccinations in ongoing outbreak zones, underscoring continued vaccine response logistics.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=ebola-virus-vaccine-market

Japan: Recent Ebola Vaccine Developments

✅ In December 2025, WHO reiterated vaccine strategies and candidate access to support Sudan ebolavirus outbreak responses, including WHO pre‐positioning of vaccine doses and trial coordination in Uganda that Japan's public health stakeholders can monitor.

✅ In October 2025, WHO published updated information confirming currently licensed Ebola vaccines (Ervebo® & Zabdeno/Mvabea®) in stockpiles for outbreak and emergency use, framing the baseline for vaccine deployment strategies worldwide.

✅ In February 2025, WHO and partners enabled access to candidate Ebola vaccines and treatments for Sudan virus disease outbreaks in Uganda, including pre‐positioning of 2,160 vaccine doses and research infrastructure for trials foundational progress impacting global preparedness.

✅ In February 2025, the first clinical efficacy trial of an Ebola Sudan virus vaccine was launched in Uganda under WHO coordination, using a ring‐vaccination approach the first of its kind for this virus species.

Recent & Upcoming Ebola Vaccine Projects

✅ In December 2025, the Ebola Vaccine Emergency Stockpile saw updated allocations and expiry planning for doses into 2026-2028, ensuring continued global readiness and deployment capacity for outbreak response.

✅ In October 2025, the Gavi Vaccine Alliance expanded preventive Ebola vaccination programmes, enabling lower‐income countries at highest risk to begin routine preventive campaigns alongside outbreak response efforts.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/ebola-virus-vaccine-market?sb

Emerging Vaccine Development Projects

✅ In October 2025, Dei BioPharma (Uganda) announced innovation plans for new mRNA Ebola and Mpox vaccines and is progressing toward vaccine manufacturing capability and facility designation in Africa.

Key Players:

=> Johnson & Johnson, Merck & Co., Inc., GSK plc., CansinoBl0, and AIM ImmunoTech Inc. among others.

Key Segments:

By Strain Type

Zaire Ebolavirus dominates the market with a 55% share, driven by the high prevalence of outbreaks in Africa, global preparedness initiatives, and the availability of approved vaccines targeting this strain.
Sudan Virus accounts for 25%, supported by rising research focus and preventive vaccination programs in high-risk regions.
Taï Forest Virus represents 10%, primarily due to its sporadic outbreaks and limited clinical cases.
Others make up 10%, including Bundibugyo virus and other rare Ebolavirus strains, driven by emerging research and surveillance programs.

By Vaccine Type

rVSV-ZEBOV leads with 50% share, being the first FDA and WHO-approved vaccine for Zaire Ebolavirus and widely deployed during outbreak responses.
Ad26.ZEBOV and MVA-BN-Filo account for 30%, supported by use in preventive vaccination campaigns and development for broader strain coverage.
Others represent 20%, including experimental and in-development vaccines under clinical trials targeting multiple strains.

By End-User

Hospitals hold 45%, driven by vaccination programs for healthcare workers and patient management during outbreaks.
Specialized Clinics account for 35%, focused on immunization programs, research centers, and outbreak containment strategies.
Others make up 20%, including government immunization centers, NGOs, and mobile vaccination units in remote areas.

By Region

North America - 30% Share
North America leads due to strategic stockpiling, outbreak preparedness, and research & development initiatives.

Europe - 25% Share
Europe accounts for 25%, supported by clinical research facilities, vaccine approval frameworks, and international aid programs.

Asia Pacific - 20% Share
Asia Pacific represents 20%, driven by increasing focus on epidemic preparedness, regional clinical trials, and vaccine awareness campaigns.

Latin America - 10% Share
Latin America holds 10%, supported by preventive programs and emerging partnerships with international health organizations.

Middle East & Africa - 15% Share
Middle East & Africa account for 15%, driven by outbreak-prone zones, government vaccination drives, and international aid programs targeting Ebolavirus containment.

FAQ

What is the current size of the Ebola Virus Vaccine Market?

A: In 2024, the Ebola Virus Vaccine Market was valued at US$173.82 million, reflecting its strong industry presence.

Q2: How large is the Ebola Virus Vaccine Market expected to be by 2033?

A: By 2033, industry forecasts suggest the Ebola Virus Vaccine Market will grow to around US$288.41 million, demonstrating significant expansion.

Q3: What is the growth rate of the Ebola Virus Vaccine Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 6.4 % during the forecast period from 2025 to 2033.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.